Click here to print this page

Planning Retirement Online

 

Breakthrough drug for Huntington’s may have implication for Alzheimer’s and other diseases

January 2018

woman comforting man

The development of a new drug that stops Huntington’s disease is now being talked about as one of the biggest medical breakthroughs in half a century.

This is not just for its amazing potential for sufferers of Huntington’s disease but because there is also potential for it to be developed further into personalised treatments for a range of patients with severe genetic diseases.

Huntington’s is an incurable degenerative disease caused by a defect in a single gene that is passed down through families. The first symptoms don’t usually appear until middle age but there is a gradual onset of uncontrolled jerky movements, dementia and ultimately paralysis. About 10,000 people in the UK have the condition and around 25,000 are at risk. Patients usually die within 20 years after the onset of symptoms.

The drug, called Ionis-HTTRx, was developed by the California biotech company Ionis Pharmaceuticals and is based on its ability to intercept and destroy a messenger molecule that spreads the instructions from the faulty Huntington gene. The drug intercepts this messenger molecule and destroys it before it can instruct a toxic protein to be made, effectively silencing the effects of the mutant gene.

Following development of the drug, it was then put into a limited trial co-ordinated by University College London’s Huntington’s Disease Centre. 46 men and women in UK, Germany and Canada were involved in the trials, all suffering from early stage Huntington’s disease. They were each given four spinal injections one month apart and the drug does was increased at each session. Around a quarter of the participants had a placebo instead.

After being given the drug, the concentration of the harmful protein in the spinal cord fluid had dropped significantly, and in precise proportion to the amount of the drug given. This was so closely matched that the researchers were confident the drug was having a powerful effect. There appears to be no major side effects from the drug.

One of the lead researchers in the trials was Professor Sarah Tabrizi, head of University College London’s Huntington’s Disease Centre. She said the results of the drug were probably the most significant moment in the history of Huntington’s since the faulty gene was isolated.

The Swiss pharmaceutical giant Roche has paid a $45m licence fee to take the drug forward now to clinical use and there is now excitement in other areas of the scientific world looking at the potential to adapt the drug to target other incurable brain disorders such as Alzheimer’s and Parkinson’s.



Back to LaterLife Interest Index


Bookmark This Share on Facebook Receive more like this

 

Latest Articles:

Health food of the month: Goats' meat

Goats' meat

Low in fat and high in protein, it is no wonder that goats’ meat is finally coming onto British menus.

more

AXA Health: How to tell if it’s time for a knee replacement

Having a damaged knee replaced can improve your quality of life dramatically. When you’re weighing up whether now is the right time, talking it through with your doctor should come top of your to-do list. 

more

Get in the flow with Tai Chi

man and woman doing tai chi

Did anyone out there hear of Tai Chi in the 1960s or 1970s? It was really only in the 1990s that this eastern form of martial art really started to take off globally. Now Tai Chi is practiced by an estimated 240 million people worldwide, including thousands here in the UK, and is said to be of enormous benefit especially to older people.

more

Was an alcohol free January worth it?

man drinking alcohol

Dry January is over, but no doubt there will be other ideas for giving up alcohol before the next big event, MacMillan’s Cancer’s “Go Sober for October”, kicks in. But how worthwhile is all this abstinence?

more

Back to LaterLife Health Section

Visit our Pre-retirement Courses section here on laterlife or our dedicated Retirement Courses site

Bookmark


Advertise on laterlife.com



LaterLife Travel Insurance in Association with Avanti